Anticorps Recombinant de lapin anti-Phospho-POLR2A (Ser5)

Phospho-POLR2A (Ser5) Recombinant Antibody for WB, IF/ICC, FC (Intra), ELISA, ChIP-qPCR

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

WB, IF/ICC, FC (Intra), ELISA, ChIP-qPCR

Conjugaison

Non conjugué

CloneNo.

241914E5

N° de cat : 84834-1-RR

Synonymes

Phospho POLR2A, Phospho POLR2A (Ser5), Phospho-POLR2A, phospho-polymerase II, Phospho-Rpb1 CTD

---

Galerie de données de validation

• 

  WB analysis using 84834-1-RR

  Non-treated HeLa cells, phosphatase inhibitor treated HeLa cells and λ phosphatase treated HeLa cells were subjected to SDS PAGE followed by western blot with 84834-1-RR (Phospho-POLR2A (Ser5) antibody) at dilution of 1:10000 incubated at room temperature for 1.5 hours. The membrane was stripped and re-blotted with Lamin B1 (66095-1-Ig) antibody as a loading control.

• 

  IF Staining of HeLa using 84834-1-RR

  Immunofluorescent analysis of (-20°C Ethanol) fixed HeLa cells using Phospho-POLR2A (Ser5) antibody (84834-1-RR, Clone: 241914E5 ) at dilution of 1:400 and CoraLite®488-Conjugated Goat Anti-Rabbit IgG(H+L) (SA00013-2).

• 

  FC experiment of HeLa using 84834-1-RR

  1X10^6 HeLa cells untreated (dashed lines) or treated with λ phosphatase which intracellularly stained with 0.13 ug Phospho-POLR2A (Ser5) Recombinant antibody (84834-1-RR, Clone:241914E5) and CoraLite®488-Conjugated Goat Anti-Rabbit IgG(H+L) (SA00013-2)(red), or 0.13 ug Rabbit IgG Isotype Control RecAb (98136-1-RR, Clone: 240953C9) (blue). Cells were fixed with 4% PFA and permeabilized with 90% MeOH.

• 

  ChIP experiment of HeLa using 84834-1-RR

  Chromatin was prepared from HeLa cells. Cells were fixed with formaldehyde for 10 minutes. The ChIP was performed with 20 µg of cross-linked chromatin, 5 µg of Phospho-POLR2A (Ser5) (84834-1-RR) or 5 ug of Normal Rabbit IgG (98136-1-RR), and 20 µl of Protein A Magarose Beads. The immunoprecipitated DNA was quantified by real-time PCR.

---

Applications testées

• Résultats positifs en WB: cellules HeLa, cellules HeLa traitées à la λ phosphatase
• Résultats positifs en IF/ICC: cellules HeLa,
• Résultats positifs en FC (Intra): cellules HeLa traitées à la λ phosphatase,
• Résultats positifs en ChIP-qPCR: cellules HeLa,

Dilution recommandée

• Western Blot (WB): WB : 1:5000-1:50000
• Immunofluorescence (IF)/ICC: IF/ICC : 1:200-1:800
• Flow Cytometry (FC) (INTRA): FC (INTRA) : 0.13 ug per 10^6 cells in a 100 µl suspension
• CHImmunoprécipitation (IP)-QPCR: CHIP-QPCR : 1:10-1:100

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Informations sur le produit

84834-1-RR cible Phospho-POLR2A (Ser5) dans les applications de WB, IF/ICC, FC (Intra), ELISA, ChIP-qPCR et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Hôte / Isotype: Lapin / IgG
• Clonalité: Recombinant
• Type: Anticorps
• Immunogène: Peptide
• Nom complet: polymerase (RNA) II (DNA directed) polypeptide A, 220kDa
• Masse moléculaire calculée: 1970 aa, 217 kDa
• Poids moléculaire observé: 270 kDa
• Numéro d’acquisition GenBank: BC137231
• Symbole du gène: POLR2A
• Identification du gène (NCBI): 5430
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Protein A purfication
• Tampon de stockage: PBS with 0.02% sodium azide and 50% glycerol
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

RNA Pol II consists of 12 subunits and is responsible for the expression of mRNA and lincRNA genes within cells. The subunits of RNA polymerases have been shown to play specific roles in Pol II CTD dephosphorylation, tissue-specific transcription, mRNA decay, and translation. Pol II transcription involves initiation through recruitment and CTD serine 5 phosphorylation, elongation with CTD serine 2 phosphorylation, and termination. (PMID: 38842922)

{{ptg:RelatedPrimaryAntibodies}}